We are live on ! Find out more
LCTX icon

Lineage Cell Therapeutics
LCTX

107 hedge funds and large institutions have $113M invested in Lineage Cell Therapeutics in 2018 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 33 increasing their positions, 21 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

57% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 21

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

1.31% less ownership

Funds ownership: 50.87% → 49.55% (-1.3%)

7% less funds holding

Funds holding: 115 → 107 (-8)

25% less capital invested

Capital invested by funds: $152M → $113M (-$38.5M)

34% less call options, than puts

Call options by funds: $109K | Put options by funds: $164K

47% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 17

Holders
107
Holders Change
-8
Holders Change %
-6.96%
% of All Funds
2.45%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
9
Increased
33
Reduced
21
Closed
17
Calls
$109K
Puts
$164K
Net Calls
-$55K
Net Calls Change
-$265K

Top Buyers

1
BlackRock
BlackRock
New York
+$1.33M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$556K
3
State Street
State Street
Massachusetts
+$417K
4
Two Sigma Investments
Two Sigma Investments
New York
+$147K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$124K

Top Sellers

1
Renaissance Technologies
Renaissance Technologies
New York
-$1.45M
2
DWM
Destination Wealth Management
California
-$1.42M
3
Deutsche Bank
Deutsche Bank
Germany
-$1M
4
MHP
Manatuck Hill Partners
Connecticut
-$747K
5
LCM
Laurion Capital Management
New York
-$472K
Name Holding Trade Value Shares
Change 		Change in
Stake
SXL
76
Summit X LLC
Missouri
$24K +$1.15K +571 +4%
ProShare Advisors
77
ProShare Advisors
Maryland
$24K +$1.67K +829 +7%
ARTA
78
A.R.T. Advisors
New York
$23K -$176K -87,331 -87%
OCAM
79
Onex Canada Asset Management
Ontario, Canada
$21K -$4.14K -2,057 -15%
DWA
80
Douglass Winthrop Advisors
New York
$21K – – –
ISB
81
Iowa State Bank
Iowa
$21K – – –
QPWM
82
Quadrant Private Wealth Management
Pennsylvania
$21K – – –
LPL Financial
83
LPL Financial
California
$21K +$23.4K +11,606 New
Royal Bank of Canada
84
Royal Bank of Canada
Ontario, Canada
$14K +$9.37K +4,655 +155%
LTFS
85
Ladenburg Thalmann Financial Services
Florida
$13K – – –
AIP
86
Ameritas Investment Partners
Nebraska
$12K – – –
RE
87
RBC Europe
United Kingdom
$11.7K +$13.1K +6,515 New
Zurich Cantonal Bank
88
Zurich Cantonal Bank
Switzerland
$11K – – –
CHP
89
Cable Hill Partners
Oregon
$10K – – –
Canada Life
90
Canada Life
Manitoba, Canada
$10K – – –
Bank of Montreal
91
Bank of Montreal
Ontario, Canada
$10K +$1.46K +727 +14%
FANJ
92
Financial Architects (New Jersey)
New Jersey
$8K +$9.21K +4,572 New
BNP Paribas Financial Markets
93
BNP Paribas Financial Markets
France
$7.08K -$39.4K -19,553 -83%
AG
94
Advisor Group
Arizona
$7K – – –
FDCDDQ
95
Federation des caisses Desjardins du Quebec
Quebec, Canada
$6.18K – – –
RFA
96
Reilly Financial Advisors
California
$4K – – –
TWA
97
TCI Wealth Advisors
Arizona
$3K – – –
PIA
98
Piedmont Investment Advisors
North Carolina
$3K +$3.58K +1,777 New
PCM
99
Poehling Capital Management
Wisconsin
$2K – – –
SPIA
100
Steward Partners Investment Advisory
New York
$2K – – –
1 2 3
4
5

LCTX Hedge Fund Activity: Q2 2018 in Review

107 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q2 2018, worth a combined $113M — down 25% from $152M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of LCTX and 9 opened new positions — a net loss of 8 holders — while 21 trimmed existing stakes and 33 added.

The largest buyer was BlackRock, adding an estimated $1.33M. The largest seller was Renaissance Technologies, cutting an estimated $1.45M.

  • 107 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q2 2018, down from 115 in Q1 2018.
  • Funds reported $113M of Lineage Cell Therapeutics stock for Q2 2018, down 25% quarter-over-quarter.
  • 9 funds opened new Lineage Cell Therapeutics positions in Q2 2018 and 17 closed out, a net change of -8 holders.
  • The largest Lineage Cell Therapeutics buyer in Q2 2018 was BlackRock, an estimated $1.33M added.
  • The largest Lineage Cell Therapeutics seller in Q2 2018 was Renaissance Technologies, an estimated $1.45M sold.

Based on aggregated 13F filings for Q2 2018.